November Issue: Histology-Tailored Approach to Soft Tissue #Sarcoma Alessandro Gronchi rdcu.be/dY7rP Meredith Gunder, MD Syed A. Ahmad

Congrats to our dream team🎆 🚨More downloads noted Annals of Surgical Oncology articles posted by the #SocialMedia Committee after normalization OncoAlert Raja Narayan, MD MPH Syed A. Ahmad Tracey Pu, MD @lindSLUe Kelly McMasters, MD, PhD Meredith Gunder, MD, MS Zaid Abdelsattar, MD, MS, FACS Thuy Tran, MD link.springer.com/article/10.124…

The CFP may have a 3-loss team in the field this season. If it comes down to these 2, which looks more impressive?

Original Article: Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer (CheckMate 8HW) nej.md/4eGp1tj #Oncology

Featured: Outcomes of #NeoadjuvantChemotherapy for Invasive Intraductal Papillary #MucinousNeoplasm Compared with de Novo #PancreaticAdenocarcinoma . Amro Abdelrahman, MBBS, MS Cornelius A. Thiels Sean Cleary ow.ly/IL5g50Ui7Xa Jin He Syed A. Ahmad

December Issue: Surgical Complications After #NeoadjuvantTreatment for Borderline Resectable #PancreaticCancer : From Benchmarks to Randomized Clinical Trials Kjetil Søreide Sanjay Pandanaboyana rdcu.be/d3mw7 Dra. Jordana B Vilela Syed A. Ahmad

Signatera and possibly other ctDNA assays are NOT sufficient in the surveillance of resected colorectal cancer. The benefit may still exist but are quite limited and imaging is THE STANDARD approach in monitoring resected colorectal cancer. jamanetwork.com/journals/jaman…

December Issue: Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal #PeritonealMetastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( #CRSHIPEC ) Niccolò Allievi rdcu.be/d5gtH Kurt Schultz Syed A. Ahmad

Excellent overview by Jeffrey Farma Annals of Surgical Oncology Practice Guidelines Series: Adjuvantand Neoadjuvant Therapy for Melanoma. Annals of Surgical Oncology link.springer.com/article/10.124… pubmed.ncbi.nlm.nih.gov/39495363/

Metastatic patterns stratify patients with pancreatic cancer ⁦Nature Cancer ⁦Andrew Waters⁩ nature.com/articles/s4301…

ICYMI: This is the 1st study to identify a prognostic association of chemotherapy dose density with overall survival in patients undergoing perioperative chemotherapy and surgery for resectable PDAC. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Syed A. Ahmad Davendra Sohal Flavio G Rocha, MD, FACS, FSSO OncoAlert

April Issue: Defining Textbook Outcomes for Minimally Invasive Surgical Resection of Small Gastrointestinal #StromalTumors (GIST) of the Stomach Graham J. Spurzem Jason Sicklick Chandrajit Raut rdcu.be/ei24Z Meredith Gunder, MD Syed A. Ahmad

May is Melanoma Cancer awareness month #SSOCommunity #Melanoma #SurgicalOncologists

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

Infact we have 6 regimens now in advanced HCC . Nivo plus IPI data ( checkmate 9DW ) updated for comparison OncoAlert

Stable OR teams contribute to better outcomes🤝✨ Each additional case done by same anesthesiologist-surgeon team 👉 ⬇️ major morbidity 🔓‼Opportunity is knocking: ⬆️outcomes by re-organizing teams How to do it? 🆕📝JAMA Surgery tinyurl.com/yx44pm96

Serum EV-MDM2 DNA was significantly higher in liposarcoma patients vs controls and dropped after resection—suggesting its promise as a recurrence biomarker. journals.lww.com/annalsofsurger…

Intra operative revision of +ve margin ⬆️ survival in gastric & GE junction adenoCa ✔️ R0 resection remains crucial ✔️ Even in locally advanced cases, margin revision improves outcomes—esp. in N0/N1 disease 🔗 doi.org/10.1016/j.gass… Shailesh V. Shrikhande JOGS Timothy M. Pawlik

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research

Our new Surg Onc text for students is finally in print and available! Grateful to Jeffrey Farma for the opportunity and huge appreciation for all the co-authors (too many to tag, you all rock🙏🏻). Check it out on the Amazon store 📚 AAMC Society of Surgical Oncology American Board of Surgery